Zobrazeno 1 - 2
of 2
pro vyhledávání: '"on behalf of the CanREValue Collaboration Reassessment and Uptake Working Group"'
Autor:
Wei Fang Dai, Vanessa Arciero, Erica Craig, Brent Fraser, Jessica Arias, Darryl Boehm, Nevzeta Bosnic, Patricia Caetano, Carole Chambers, Barry Jones, Elena Lungu, Gunita Mitera, Tanya Potashnik, Anthony Reiman, Trevor Ritcher, Jaclyn M. Beca, Avram Denburg, Rebecca E. Mercer, Ambica Parmar, Mina Tadrous, Pam Takhar, Kelvin K. W. Chan, on behalf of the CanREValue Collaboration Reassessment and Uptake Working Group
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 4174-4183 (2021)
The Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) Collaboration was established to develop a framework for generating and using real-world evidence (RWE) to inform the reassessment of cancer drugs following initial health techno
Externí odkaz:
https://doaj.org/article/9c275cad03714dd78f5a9502b73ba44d
Autor:
Dai WF; Temerty Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada.; Canadian Centre for Applied Research in Cancer Control, Toronto, ON M5G 2L3, Canada., Arciero V; Temerty Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada., Craig E; New Brunswick Cancer Network, Saint John, NB E2J 3S4, Canada., Fraser B; Canadian Agency for Drugs and Technologies in Health, Ottawa, ON K1S 5S8, Canada., Arias J; Ontario Health (CCO), Toronto, ON M5G 2L7, Canada., Boehm D; Saskatchewan Cancer Agency, Regina, SK S4W 0G3, Canada., Bosnic N; Patented Medicine Prices Review Board, Ottawa, ON K1P 1C1, Canada., Caetano P; Government of Manitoba, Winnipeg, MB R3B 3M9, Canada., Chambers C; Alberta Health Services, Edmonton, AB T5J 3E4, Canada., Jones B; Health Canada, Ottawa, ON K1Y 4X2, Canada., Lungu E; Patented Medicine Prices Review Board, Ottawa, ON K1P 1C1, Canada., Mitera G; Canadian Association of Provincial Cancer Agencies, Toronto, ON M5H 1J9, Canada., Potashnik T; Patented Medicine Prices Review Board, Ottawa, ON K1P 1C1, Canada., Reiman A; Department of Medicine, Dalhousie University, Halifax, NS B3H 2Y9, Canada.; Department of Biology, University of New Brunswick, Fredericton, NB E3B 5A3, Canada.; Department of Oncology, Saint John Regional Hospital, Saint John, NB E2L 42L, Canada., Ritcher T; Canadian Agency for Drugs and Technologies in Health, Ottawa, ON K1S 5S8, Canada., Beca JM; Canadian Centre for Applied Research in Cancer Control, Toronto, ON M5G 2L3, Canada.; Ontario Health (CCO), Toronto, ON M5G 2L7, Canada., Denburg A; The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada., Mercer RE; Canadian Centre for Applied Research in Cancer Control, Toronto, ON M5G 2L3, Canada.; Ontario Health (CCO), Toronto, ON M5G 2L7, Canada., Parmar A; Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada., Tadrous M; Women's College Hospital, Toronto, ON M5S 1B2, Canada., Takhar P; Ontario Health (CCO), Toronto, ON M5G 2L7, Canada., Chan KKW; Temerty Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada.; Canadian Centre for Applied Research in Cancer Control, Toronto, ON M5G 2L3, Canada.; Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada., On Behalf Of The CanREValue Collaboration Reassessment And Uptake Working Group
Publikováno v:
Current oncology (Toronto, Ont.) [Curr Oncol] 2021 Oct 16; Vol. 28 (5), pp. 4174-4183. Date of Electronic Publication: 2021 Oct 16.